Literature DB >> 6973583

Reciprocal transfer of abnormalities in clonable B lymphocytes and myeloid progenitors between NZB and DBA/2 mice.

H Jyonouchi, P W Kincade, R A Good, G Fernandes.   

Abstract

Previous studies in this laboratory revealed that NZB mice have abnormalities of myeloid progenitor populations from an early age such that they are poorly responsive to a particular type of colony-stimulating activity (CSA). In addition, these mice develop abnormally high numbers of B cells that can be cloned in semisolid agar cultures and that are atypical in resisting inhibition by anti-mu antibodies. To investigate whether these abnormalities, like other autoimmune phenomena studied previously, are transferrable with hemopoietic cell grafts, we performed reciprocal bone marrow transplants between NZB and normal DBA/2 mice. Irradiated control mice given syngeneic marrow did not change with respect to any of the parameters that were measured. In contrast, DBA/2 recipients of NZB marrow were indistinguishable from NZB mice in terms of CSA responses and incidences of anti-mu resistant B cells. The proportions but not total numbers of clonable B cells ere elevated in these mice until at least 16 wk after grafting. Conversely, NZB mice given DBA/2 cells had all of the normal characteristics of DBA/2 mice. Transplantation did not cause significant changes in hematocrits, reticulocyte counts, or spleen weights. Therefore, all elements necessary for expression of these lymphoid and nonlymphoid abnormalities of NZB mice are intrinsic to radiosensitive hemopoietic cells.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6973583

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  10 in total

1.  Organ-specific and systemic autoimmune diseases originate from defects in hematopoietic stem cells.

Authors:  S Ikehara; M Kawamura; F Takao; M Inaba; R Yasumizu; S Than; H Hisha; K Sugiura; Y Koide; T O Yoshida
Journal:  Proc Natl Acad Sci U S A       Date:  1990-11       Impact factor: 11.205

2.  Nonmyeloablative allogeneic bone marrow transplantation of a child with systemic autoimmune disease and lung vasculitis.

Authors:  Olcay Y Jones; Richard A Cahill
Journal:  Immunol Res       Date:  2008       Impact factor: 2.829

3.  Marrow transplantation from tolerant donors to treat and prevent autoimmune diseases in BXSB mice.

Authors:  K Himeno; R A Good
Journal:  Proc Natl Acad Sci U S A       Date:  1988-04       Impact factor: 11.205

4.  Transplantation of wheat germ agglutinin-positive hematopoietic cells to prevent or induce systemic autoimmune disease.

Authors:  E E Sardiña; K Sugiura; S Ikehara; R A Good
Journal:  Proc Natl Acad Sci U S A       Date:  1991-04-15       Impact factor: 11.205

Review 5.  Autoimmune diseases: immunopathology and etiopathogenesis.

Authors:  A N Theofilopoulos; F J Dixon
Journal:  Am J Pathol       Date:  1982-09       Impact factor: 4.307

6.  Rationale for bone marrow transplantation in the treatment of autoimmune diseases.

Authors:  S Ikehara; R A Good; T Nakamura; K Sekita; S Inoue; M M Oo; E Muso; K Ogawa; Y Hamashima
Journal:  Proc Natl Acad Sci U S A       Date:  1985-04       Impact factor: 11.205

7.  Long-term observations of autoimmune-prone mice treated for autoimmune disease by allogeneic bone marrow transplantation.

Authors:  S Ikehara; R Yasumizu; M Inaba; S Izui; K Hayakawa; K Sekita; J Toki; K Sugiura; H Iwai; T Nakamura
Journal:  Proc Natl Acad Sci U S A       Date:  1989-05       Impact factor: 11.205

Review 8.  Systemic lupus erythematosus: immunopathogenesis of neurologic dysfunction.

Authors:  P M Moore; R P Lisak
Journal:  Springer Semin Immunopathol       Date:  1995

9.  Age-dependent deficiency of B lymphocyte lineage precursors in NZB mice.

Authors:  H Jyonouchi; P W Kincade; K S Landreth; G Lee; R A Good; M E Gershwin
Journal:  J Exp Med       Date:  1982-06-01       Impact factor: 14.307

Review 10.  Association of lpr gene with graft-vs.-host disease-like syndrome.

Authors:  A N Theofilopoulos; R S Balderas; Y Gozes; M T Aguado; L M Hang; P R Morrow; F J Dixon
Journal:  J Exp Med       Date:  1985-07-01       Impact factor: 14.307

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.